| Budget Amount *help |
¥45,500,000 (Direct Cost: ¥35,000,000、Indirect Cost: ¥10,500,000)
Fiscal Year 2023: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2022: ¥8,710,000 (Direct Cost: ¥6,700,000、Indirect Cost: ¥2,010,000)
Fiscal Year 2021: ¥14,820,000 (Direct Cost: ¥11,400,000、Indirect Cost: ¥3,420,000)
Fiscal Year 2020: ¥19,370,000 (Direct Cost: ¥14,900,000、Indirect Cost: ¥4,470,000)
|
|---|
| Outline of Final Research Achievements |
Catalyst 1 was administered intravenously to 11-month-old Alzheimer's disease model mice and irradiated with 600 nm light 1 hour later. This procedure was repeated five times, and homogenate samples derived from the mouse hippocampus were evaluated by Western blotting. The results showed that Aβ dimer, produced by oxygenation was more strongly detected in the catalyst-treated and light-irradiated mice than in the catalyst-only mice, suggesting that Catalyst 1 promotes the photooxygenation of Aβ in the in vivo system. Catalytic photooxygenation reduced the amount of amyloid in the mouse brain by approximately 30%, indicating that this is due to enhanced degradation of oxygenated Aβ by microglial cells in the brain.
|
